Biotech | March 01, 2022
Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
High level of vaccine efficacy maintained over a 6-month period of surveillance
High level of vaccine efficacy maintained over a 6-month period of surveillance
As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
Subscribe To Our Newsletter & Stay Updated
